Skip to main content

True-EBV negative MS is not MS


I have almost completed a paper with a colleague and friend Viqar Chamoun. He was a contemporary of mine when I did my PhD. Chamoun and I worked in the same laboratory and we spent many hours chewing the cud together. Chamoun is a very deep thinker and got me interested in medical philosophy and the application of logic to defining a disease. Chamoun worked on neurosarcoidosis and developed a set of logical steps to show that contemporary diagnostic criteria for neurosarcoidosis were based on tautology. Despite his logical approach we never got his seminal paper published. The plan is to publish it now and in parallel with a paper defining MS as a biological disease and setting-out the principles of how we should incorporate biomarkers into the diagnostic criteria to improve both the sensitivity and specificity of the current criteria.

Viqar Chamoun - thinker extraordinaire
 
Surprise, surprise one of the biomarkers we want to explore is EBV seropositivity. However, to validate a new set of diagnostic criteria to define MS as biological rather than a clinico-radiological construct will require a post-mortem study and will take decades to complete. I am also not sure the wider MS community is ready for us to redefine MS as a biological disease.

I am not surprised by the study below that found paediatric anti-MOG syndrome masquerading as MS. Diagnosing MS is always difficult in children. Please remember even if you fulfil the contemporary definition of having MS at post-mortem about 1 in 20 of you will not have MS and I suspect this will be even higher in children with MS. I have been saying for years that true EBV negative MS is not MS. When I say true EBV-negative MS is that you have to remember that standard diagnostic assays for detecting anti-EBV antibodies are not 100% sensitive. In summary, it is very difficult to find true-EBV negative people with MS.

I have had a recurring dream of finding and studying a cohort of true EBV-negative MS patients, but there are too few such patients to study. When we found 32 patients, in our large international CIS study of over 1000 patients, who were seronegative for EBV we shipped their samples to Jaap Middledorp’s EBV laboratory in Amsterdam for more detailed testing. When the results came back 31 of the 32 were positive and one was equivocal with Jaap’s more sensitive assays.

So yes I think ‘true-EBV negative MS is not MS’ and that applies to paediatric MS as well. The data below is very important and strongly supports EBV as being the cause of MS and is screaming out for us to start our EBV-vaccine MS prevention study ASAP. Do you agree?

Bardia Nourbakhsh et al. MS is rare in EBV-seronegative children with CNS inflammatory demyelination. Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062. Online ahead of print.

Although Epstein-Barr virus (EBV) is hypothesized to be a prerequisite for multiple sclerosis (MS), up to 15% of children with a diagnosis of MS were reported to be EBV-seronegative. When re-evaluating 25 EBV-seronegative children out of 189 pediatric patients with a diagnosis of clinically isolated syndrome/MS, we found anti-myelin oligodendrocyte glycoprotein (MOG) antibody in 11/25 (44%) EBV-seronegative, but only 9/164 (5.5%, p < 0.001) EBV-seropositive patients. After critical review, MS remained a plausible diagnosis in only four of 14 EBV-seronegative/MOG antibody-negative patients. In children with an MS-like presentation, EBV seronegativity should alert clinicians to consider diagnoses other than MS, especially MOG-antibody disease. This article is protected by copyright. All rights reserved.

CoI: multiple

Twitter: @gavinGiovannoni                         Medium: @gavin_24211

Labels:

Comments

  1. Anonymous23 March 2021 at 10:35

    Prof G what antibody tests do you recommend for detecting EBV?

    ReplyDelete
  2. Gavin Giovannoni29 March 2021 at 04:20

    The standard screen is anti-EBNA-1 and anti-VCA (viral capsid antigen). If you are unsure you can do anti-EA (early antigen), but that is usually as part of IM.

    ReplyDelete
  3. Nicolas S9 April 2021 at 08:41

    Could you please share your opinion on ATA188 latest figures?

    ReplyDelete
    Replies
    1. Gavin Giovannoni13 April 2021 at 07:44

      Have yet to see the final data-cut. The treatment needs to go into a proper double-blind randomised controlled study to convince me. Nothing I have seen so far would argue against the next phase.

      Delete

Post a Comment

Popular posts from this blog

Are you ready for an EBV vaccine to prevent MS?

"Professor Giovannoni, you tell me that my daughter has a 1 in 40 chance of developing multiple sclerosis and that MS has reached epidemic proportions in parts of the world? Is there anything I can do to reduce her chances of getting MS? Is there anything we can do to stop other people from getting MS?" Although multiple sclerosis (MS) is a complex disease due to the interaction of genetic and environmental factors data on the occurrence of MS at the population level (epidemiology) supports the Epstein Barr Virus (EBV) as being necessary, but not sufficient, for someone to develop MS. In other words, EBV is probably the cause of MS. Of all the putative causative agents that have been proposed to be associated with MS, EBV is the only one where the risk of getting MS if you are EBV negative is close to zero or zero if you limit the analyses to those studies which use a technique called immunofluorescence microscopy as the gold-standard assay to detect anti-EBV antibodies. EBV ...
7 comments
Read more

Smoking: a major preventable MS risk factor

I have been complaining about my low productivity levels since I have gotten back to work after my accident. However, last night with a single one hour webinar we have managed to set-up a new international collaboration to study and address the social determinants of health (SDoH) and their impact on MS. Our focus is going to be on which SDoH can we modify and hence improve the outcome for people with MS (pwMS)? Smoking is one such modifiable factor and needs to be addressed at a (1) population level with policy and legislation, (2) at a local or community level, (3) with the family and (4) at an individual level target the people with MS (pwMS). We know that pwMS who smoke have a worse outcome than people who don’t smoke. The effect of smoking is equivalent to negating the treatment effect of being on an injectable therapy such as interferon beta. Put simply smokers with MS start using a walking stick (EDSS = 6.0) about 6 years earlier than pwMS who don’t smoke. Getting pwMS to stop s...
7 comments
Read more

Corpulence and poverty

Since stating my intention to join the  #BackTo21  campaign to get my BMI back to what it was when I was 21 years of age, I have had several emails and direct messages on social media questioning the wisdom of my intention.  Photo by NeONBRAND on Unsplash It is clear that despite BMI being a relatively poor metric of health there is overwhelming evidence that at a population level it predicts poor health outcomes. Importantly there is new data that indicates the target BMI for the prevention of type 2 diabetes and the metabolic syndrome depends on your ethnicity. For people of South Asian origin, there is a call to reset the BMI cutoff to 23.9, which for most people is within the normal range. At the same time, there is a call to classify obesity as an important social determinant of health. Arnaud Chiolero argues below for using BMI as a socioeconomic indicator. Do you agree? Isn’t it quite amazing that in a previous era corpulence was a sign of affluence, whereas in th...
4 comments
Read more